State Street’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-43,894
| Closed | -$29K | – | 4384 |
|
|
2024
Q2 | $29K | Buy |
43,894
+13,844
| +46% | +$8.62K | ﹤0.01% | 4234 |
|
|
2024
Q1 | $18.1K | Hold |
30,050
| – | – | ﹤0.01% | 4293 |
|
|
2023
Q4 | $17.7K | Hold |
30,050
| – | – | ﹤0.01% | 4357 |
|
|
2023
Q3 | $20K | Hold |
30,050
| – | – | ﹤0.01% | 4440 |
|
|
2023
Q2 | $98.9K | Sell |
30,050
-100,488
| -77% | -$304K | ﹤0.01% | 4245 |
|
|
2023
Q1 | $1.19M | Buy |
130,538
+255
| +0.2% | +$3.61K | ﹤0.01% | 3478 |
|
|
2022
Q4 | $1.53M | Sell |
130,283
-23,560
| -15% | -$416K | ﹤0.01% | 3450 |
|
|
2022
Q3 | $3.26M | Buy |
153,843
+21,117
| +16% | +$569K | ﹤0.01% | 3259 |
|
|
2022
Q2 | $3.22M | Sell |
132,726
-407,834
| -75% | -$13.9M | ﹤0.01% | 3311 |
|
|
2022
Q1 | $26.9M | Buy |
540,560
+128,156
| +31% | +$6.33M | ﹤0.01% | 2183 |
|
|
2021
Q4 | $29M | Buy |
412,404
+5,885
| +1% | +$496K | ﹤0.01% | 2198 |
|
|
2021
Q3 | $37.9M | Sell |
406,519
-15,458
| -4% | -$1.47M | ﹤0.01% | 2011 |
|
|
2021
Q2 | $42.4M | Sell |
421,977
-200,732
| -32% | -$19.6M | ﹤0.01% | 1972 |
|
|
2021
Q1 | $58.1M | Sell |
622,709
-120,412
| -16% | -$12.2M | ﹤0.01% | 1630 |
|
|
2020
Q4 | $61.3M | Buy |
743,121
+124,445
| +20% | +$10.6M | ﹤0.01% | 1511 |
|
|
2020
Q3 | $53.1M | Buy |
618,676
+520,315
| +529% | +$60.6M | ﹤0.01% | 1418 |
|
|
2020
Q2 | $9.15M | Buy |
98,361
+19,615
| +25% | +$1.08M | ﹤0.01% | 2464 |
|
|
2020
Q1 | $2.24M | Buy |
78,746
+10,334
| +15% | +$402K | ﹤0.01% | 3012 |
|
|
2019
Q4 | $2.83M | Buy |
68,412
+18,554
| +37% | +$406K | ﹤0.01% | 3117 |
|
|
2019
Q3 | $705K | Buy |
49,858
+2,061
| +4% | +$43.2K | ﹤0.01% | 3459 |
|
|
2019
Q2 | $1.68M | Buy |
47,797
+44,850
| +1,522% | +$2.43M | ﹤0.01% | 3305 |
|
|
2019
Q1 | $165K | Buy |
+2,947
| New | +$159K | ﹤0.01% | 3591 |
|
|
2018
Q3 | – | Sell |
-1,217
| Closed | -$100K | – | 3808 |
|
|
2018
Q2 | $100K | Sell |
1,217
-13,486
| -92% | -$1.3M | ﹤0.01% | 3632 |
|
|
2018
Q1 | $1.55M | Buy |
14,703
+2,627
| +22% | +$313K | ﹤0.01% | 3256 |
|
|
2017
Q4 | $1.55M | Buy |
12,076
+4,022
| +50% | +$494K | ﹤0.01% | 3260 |
|
|
2017
Q3 | $930K | Buy |
8,054
+1,694
| +27% | +$203K | ﹤0.01% | 3392 |
|
|
2017
Q2 | $831K | Buy |
+6,360
| New | +$858K | ﹤0.01% | 3361 |
|
State Street's VBIV Position: Q3 2024 in Review
State Street sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2024, closing a stake of 43,894 shares — an estimated $29K sold.
State Street first reported a position in VBIV in Q2 2017 and held it in 27 quarters. The position peaked at $61.3M in Q4 2020. 1 fund tracked by Wall St. Rank holds VBIV as of Q3 2024.
- State Street reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2024 after selling out during the quarter.
- State Street sold 43,894 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2024, an estimated $29K.
- State Street first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2017 and held it in 27 quarters.
- State Street's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $61.3M in Q4 2020.
- 1 fund tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2024.
Based on State Street's 13F filing for Q3 2024, filed 14 Nov 2024.